Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Up 6.4% – Should You Buy?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares shot up 6.4% during trading on Monday . The stock traded as high as $3.95 and last traded at $3.95. 96,933 shares were traded during mid-day trading, a decline of 94% from the average session volume of 1,741,280 shares. The stock had previously closed at $3.71.

Analyst Ratings Changes

Several brokerages have weighed in on IRWD. Craig Hallum cut their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $10.00.

Ironwood Pharmaceuticals Stock Performance

The company has a fifty day moving average of $3.89 and a 200-day moving average of $4.52.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The firm had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s revenue for the quarter was down 19.4% on a year-over-year basis. During the same period last year, the business earned $0.12 earnings per share. As a group, analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the transaction, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at $1,263,053.76. This represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 12.90% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. KBC Group NV raised its stake in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares in the last quarter. Journey Strategic Wealth LLC bought a new position in Ironwood Pharmaceuticals in the 4th quarter worth $45,000. Wolverine Trading LLC acquired a new position in Ironwood Pharmaceuticals during the 3rd quarter worth $51,000. Diversified Trust Co bought a new stake in Ironwood Pharmaceuticals during the third quarter valued at about $52,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $53,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.